PRMT5 and hepatocellular carcinoma: PRMT5 silencing in MYC-overexpressing hepatocellular carcinoma cells directly regulated MHC-II expression by decreasing the in vitro H3R8me2s and H4R3me2s enrichment on CIITA and CD74 promoters (50).